Synthesis and biological evaluation of Combretastatin A-4 derivatives containing a 3’-O-substituted carbonic ether moiety as potential antitumor agents by unknown
Ma et al. Chemistry Central Journal 2013, 7:179
http://journal.chemistrycentral.com/content/7/1/179RESEARCH ARTICLE Open AccessSynthesis and biological evaluation of
Combretastatin A-4 derivatives containing a
3’-O-substituted carbonic ether moiety as
potential antitumor agents
Mingyi Ma, Longru Sun*, Hongxiang Lou and Mei JiAbstract
Background: Combretastatin A-4 (CA-4), which is an excellent antineoplastic agent, was isolated from Combretum
caffrum. To date, structural modification studies of CA-4 have focused predominantly on the construction of new
therapeutic agents for drug discovery. As a part of our ongoing work towards the modification of natural products,
we have focused on the 3’-O-substituent groups in the B-ring of CA-4 under the hypothesis that these novel
derivatives will possess good bioactivities and behave as effective antiproliferative pro-drugs.
Results: A series of novel CA-4 derivatives, which contained a 3’-O-substituted carbonic ether moiety, were
synthesized and evaluated for their antitumor activities against four tumor cell lines, including MDA-MB-231, MCF-7,
K562 and A549 cells. These derivatives exhibited clear antitumor activities, and CA-4E, in particular, showed the
highest bioactivity of all of the derivatives tested against all four tumor cell lines, with IC50 values in the range of 1
to 180 nM. Based on its high bioactivity, CA-4E was subsequently selected to investigate the antitumor mechanism
of these synthetic compounds. The cell cycle results demonstrated that CA-4E induced time- and dose-dependent
G2/M arrest in a similar manner to CA-4, although its effect was more powerful than that of CA-4, and the apoptosis
data showed that CA-4E induced cellular apoptosis in a dose-dependent manner.
Conclusions: The newly synthesized CA-4 derivatives exhibited good antitumor activities in vitro, with CA-4E, in
particular, showing the highest bioactivity of all of the compounds tested. Furthermore, CA-4E induced time- and
dose-dependent G2/M arrest and cellular apoptosis in a dose-dependent manner. Taken together, these results
suggest that CA-4E should be subjected to further investigation as a potential anticancer drug candidate.
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Combretastatin A-4 (CA-4, Figure 1) is a natural product,
which was first isolated from the bark of the South African
tree Combretum caffrum by Pettit et al. in 1989 [1]. As a
potentially effective vascular disrupting agent (VDA), CA-4
can discriminate between normal vessels and tumor vessels
and selectively disrupt the abnormal tumor vasculature,
leading ultimately to vascular collapse [2-4]. Furthermore,
CA-4 exhibits excellent anticancer properties by interfering* Correspondence: sunlr@sdu.edu.cn
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reproduction in any medium, provided the orwith the dynamics of tubulin, in that CA-4 inhibits the
polymerization of tubulin by binding to the colchicine site,
which results in cell mitotic arrest [5]. The activity of the
trans isomer of CA-4 (Figure 1), however, is much lower
than that of CA-4. For example, CA-4 displays cytoto-
xicity at low nanomolar concentrations, whereas the trans
isomer inhibits cell growth in the micromolar range [6].
CA-4 has recently been the subject of considerable
interest from pharmaceutical chemists attempting to de-
sign new compounds capable of mimicking the bioactivity
of CA-4, and a wide variety of analogues and derivatives
of CA-4 have been synthesized and evaluated for their
antitumor activities in vitro. Based on these derivatives,td. This is an open access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 Structures of CA-4, the trans isomer of CA-4 and CA-4 phosphate.
Figure 2 Structure-activity relationships of a tubulin binder.
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http://journal.chemistrycentral.com/content/7/1/179several structure–activity relationships (SARs) have been
identified for CA-4, which are summarized in Figure 2.
These SARs have demonstrated that the 3,4,5-trimethoxy-
substituted A-ring and the cis configuration of the stilbene
connecting the A-ring to the B-ring are both essential to
the antiproliferative activity of these compounds [7-9].
The 3’-hydroxy group of B-ring has been shown to be
non-essential for the interaction of CA-4 with tubulin,
and this particular moiety could potentially be replaced
with other suitable substituents [10]. A series of CA-4
derivatives bearing different substituents at the 3’-position
of the B-ring, such as a halogen atom (e.g., fluorine or
bromine), amine, boronic acid, nitro, amide, alkoxy or acyl
group, were synthesized and evaluated for their antitumor
activities [11-13]. Among these derivatives, a water soluble
pro-drug of CA-4, CA-4 phosphate (CA-4P, Figure 1), was
identified and progressed into clinical trials as a potential
vascular disrupting agent that could be used in combi-
nation with conventional cytotoxic therapies for the treat-
ment of cancer [14]. With this in mind, and as part of our
ongoing work towards the synthesis of natural product
derivatives with interesting biological properties, we have
focused our attention on modifying the 3’-O-substituent
groups in the B-ring of CA-4. It is envisaged that these
novel derivatives would posses good bioactivities com-
pared to CA-4, and that they could be used as potential
antiproliferative pro-drugs. Herein, we describe the design,
synthesis and evaluation of the cytotoxicity of a series of
novel Combretastatin A-4 derivatives. Furthermore, the
most active of these compounds, CA-4E, was selected to




CA-4 is recognized as an important parent com-
pound, in terms of its biological effects, and hundreds
of structural modified CA-4 derivatives have been
synthesized and reported [15,16], where the modifica-
tions have traditionally been affected using either a
Wittig reaction or a Perkin condensation reaction.
Using the Wittig reaction, the CA-4 product is gener-
ally formed as a mixture with the corresponding trans iso-
mer, which can be difficult to remove, and this can lead to
complications in any follow-up work [17]. In contrast, thePerkin condensation proceeds stereoselectively to af-
ford CA-4 as the major product [18]. The use of the
Perkin condensation reaction therefore provides better
access to the CA-4 derivatives and, in contrast to the
Wittig reaction, does not require extensive purifica-
tion procedures.
Our synthetic route to the CA-4 derivatives is depicted
in Scheme 1 (Additional file 1), where the parent com-
pound CA-4 was prepared via a Perkin condensation fol-
lowing a previously described procedure [18]. A mixture
of 3,4,5-trimethoxyphenylacetic acid (1), 3-hydroxy-4-
methoxybenzaldehyde (2), triethylamine, and acetic
anhydride was heated at reflux at 140°C to give inter-
mediate 3. The reaction mixture was then hydrolyzed
using sodium hydroxide, and the cinnamic acid analogue
4 was precipitated from the solution following acidifica-
tion with concentrated hydrochloric acid. Subsequent
purification of the crude precipitate by recrystallization
from ethanol gave pure 4 in 65% yield. Compound 4
was then decarboxylated with copper powder in quin-
oline at 220°C, and the crude product was purified by
flash column chromatography (FCC) to give CA-4 in
55% yield together with a very small amount of its
trans isomer. The CA-4 derivatives 6-14, which con-
tained an O-substituted carbonic ether moiety, were
prepared via the acylation of CA-4 with the chloro-
formic acid alkyl esters 5 and pyridine, and the crude
derivatives were purified by FFC. All of the newly
synthesized compounds were characterized using their
spectra data (Additional file 2).
Biological activity evaluation
WST-1-based cell cytotoxicity assay
The in vitro cytotoxicities of the synthesized com-
pounds were evaluated against selected human cancer
Table 1 In vitro cytotoxicities against four different tumor
cell lines
Compound IC50 (nM)
MDA-MB-231 MCF-7 K562 A549
CA-4 6.27 10.49 5.75 428
6 12.29 8.00 7.68 693
7(CA-4E) 2.30 1.32 <2.50 180
8a 7.26 8.38 14.78 486
8b 7.77 7.59 14.88 476
9a 7.94 10.04 14.90 309
9b 6.68 11.29 8.76 330
10 6.40 10.39 9.42 435
11 4.39 12.46 12.28 316
12 7.27 7.09 8.85 265
13 12.23 10.85 9.65 735
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 6    R=CH3
 7    R=C2H5
8a   R=n-propyl
8b   R=isopropyl
9a   R=n-butyl
9b   R=isobutyl
10   R=n-amyl
11   R=phenyl
12   R=benzyl
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Scheme 1 Synthetic route to CA-4 and the target compounds 6-14.
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http://journal.chemistrycentral.com/content/7/1/179cell lines for breast (MDA-MB-231 and MCF-7), lung
(A549) and leukemia (K562) using a WST-1-based
colorimetric cell cytotoxicity assay [19]. All of the ex-
periments were performed in triplicate. The WST-1-
based assay was used in the current study instead of
the MTT-based assay because it is generally consid-
ered to be more rapid, sensitive and accurate than
the MTT assay. Furthermore, this assay involves the
detection of water-soluble formazan, and therefore
does not require an additional solubilization step [19].
The absorbance was measured on a microplate reader
at 450/630 nm with CA-4 being used as a positive
control. The corresponding IC50 values were calcu-
lated and are listed in Table 1.
As shown in Table 1, all of the synthesized com-
pounds exhibited good in vitro cytotoxicity against all
four of the tumor cell lines tested, with IC50 values of
less than 800 nM in all cases, except for compound
14. Compound 7 (CA-4E) showed the greatest cyto-
toxicity of all of the compounds tested against all
four cell lines with IC50 values in the range of 1 to
180 nM. It is noteworthy that CA-4E showed lower
cytotoxicities than those of CA-4. Compound 6 was
only weakly cytotoxic compared to CA-4, except
against the MCF-7 cells. Compounds 8a, 8b, 9a, 9b,
10, 11 and 12 displayed similar cytotoxicities to the
parent compound CA-4 against the MDA-MB-231,
MCF-7 and A549 cells. However, compounds 13 and
14, especially 14, showed much lower cytotoxicitiesthan CA-4, and these lower cytotoxicities were attrib-
uted to the size of the 3’-O-substituted carbonic ether
moiety, in that the long side chain in 14 most likely
prevented the binding of the active moiety to the col-
chicine site of tubulin. These results therefore sug-
gested that the modification of CA-4 with bulky
substituents at the C-3’ position would lead to a re-
duction in the activity of the inhibitors.
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those of CA-4E at the 3’-position of their B-ring, such as a
hydroxyethyl (15), chloroethyl (16), acetyl (17), methyl
(18) or chloroethyl-carbamoyl (19) group (Figure 3), were
synthesized and evaluated for their antitumor activity. As
previously reported, compounds 15, 16 and 19 exhibited
very low levels of cytotoxicity against the tumor cell lines
tested (i.e., SK-N-SH, SW1736, NCI-H460, DU-145 and
FADU cells), with IC50 values in the range of 28 to 4,700
nM, whereas CA-4 exhibited IC50 values in the range of
0.26 to 0.76 nM against the same cell lines [13]. Com-
pound 17 displayed similar cytotoxicity to CA-4 against
the murine leukemic cell line L1210, with an IC50 value of
7 × 103 nM, whereas compound 18 gave an IC50 value of
3 × 105 nM against the same cell line [20]. Taken together,
these results clearly demonstrate that CA-4E exhibited
higher levels of cytotoxicity than CA-4 against all four of
the tumor cell lines tested. Further studies would be
required, however, to determine whether the additional
activity of CA-4E was due to its carbonic acid ester
(CA-4E) or decomposition products, and potentially de-
velop a clinical useful anticancer agent.
Cell cycle analysis
In light of its remarkable antitumor activity, CA-4E was
selected as being the best representative of the synthesized
compounds and its antitumor effects on the cell cycle
were investigated further and compared to those of CA-4.
MCF-7 cells were treated with 1.5 and 3 nM of CA-4 and
CA-4E for 24 and 36 h, respectively. The cells were then
analyzed by FCM, and the results are shown in Figure 4.
The G1 phase frequencies were 75.09, 65.05 and 58.26%
after treatment with 0, 1.5, and 3 nM of CA-4 for 24 h, re-
spectively. Furthermore, the treatment of the MCF-7 cells
with 0, 1.5, and 3 nM of CA-4E led to G1 phase frequen-
cies of 75.09, 61.44 and 39.64%, respectively. The results
illustrated that treatment with CA-4 or CA-4E led to simi-
lar reductions in the number of cells in the G1 phase, and
the effect of CA-4E was more pronounced, especially at
the higher concentration. The frequencies of cells in the
G2/M phase following treatment with 0, 1.5, and 3 nM of
CA-4 were 0.74, 4.54 and 7.92%, respectively, whereas
treatment with the same concentration of CA-4E gave












Figure 3 Structures of the CA-4 derivatives.These results indicated that CA-4 and CA-4E both led to
a concentration-dependent increase in the number of cells
in the G2/M phase, with the effect of CA-4E being more
pronounced than that of CA-4, especially at the higher
concentration. Similar results were also observed for the
cells cultured for 36 h, except the number of cells in the
S phase increased after culturing for 24 h, whereas a
decrease was observed after culturing for 36 h. These re-
sults demonstrated that CA-4E induced the transfer of the
cell arrest phase from the G1 phase to the G2/M phase
via the S phase. These cell cycle analysis experiments
demonstrated that CA-4E induced both time- and dose-
dependent G2/M arrest in the same way as CA-4, but
more powerfully.
Effect on apoptosis
The effect of CA-4E on the apoptosis of MCF-7 cells was
also evaluated. MCF-7 cells were exposed to different
concentrations of CA-4E for 24 h, and the FITC-Annexin
V/PI double staining method for FCM was used to con-
struct apoptotic cell scatter plots. The results are shown
in Figure 5 (A). The apoptotic cell scatter plot was divided
into four quadrants, including the B1 quadrant, which
represents the damaged cells; B2 quadrant, which repre-
sents late apoptotic cells; B3 quadrant representing living
cells; and B4 quadrant, which represents early apoptotic
cells. The cells in the B2 and B4 quadrants were regarded
as apoptotic cells, and were used to evaluate the effect of
CA-4E on apoptosis. The total percentages of apoptotic
cells were 2.84, 8.74, 12.34 and 33.03% at concentrations
of 0, 1.5, 3 and 6 nM, respectively. As shown in Figure 5
(B), the rate of apoptosis increased sharply with increa-
sing CA-4E concentration. This result demonstrated that




FCC was performed with 200–300 mesh silica gel (10-
40 μm, Qingdao Haiyang Chemical Co. Ltd., Qingdao,
China). The reactions were monitored by thin-layer chro-
matography using silica gel GF254 plates (Qingdao Haiyang
Chemical Co. Ltd.), and the plates were visualization by












Figure 4 Effects of CA-4 and CA-4E on the cell cycle distribution of MCF-7 cells. MCF-7 cells were cultured for 24 and 36 h without any
compound (control) and with CA-4 or CA-4E at concentrations of 1.5 and 3 nM, respectively. (A) Cycle distribution of the cells was detected by
flow cytometry. (B) Average population of cells in G1, G2 24 and S phase, respectively.
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Figure 5 Apoptotic effect on MCF-7 cell line induced by CA-4E. MFC-7 cells were incubated in media containing various concentrations of
CA-4E (i.e., 0, 1.5, 3 and 6 nM) for 24 h. (A) Apoptotic cell scatter plots were constructed by flow cytometry using FITV-Annexin V/PI staining.
(B) Rate of apoptotic cells at different concentrations of CA-4E.
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http://journal.chemistrycentral.com/content/7/1/179melting point apparatus (Beijing, China). NMR spectra
were recorded on a Bruker Avance 300 MHz NMR spec-
trometer (Bruker, Billerica, Massachusetts, USA) at 300
(1H) and 75 (13C) MHz using TMS as an internal
reference standard. HRMS were conducted on an LTQ-
Qrbitrap XL (Thermo-Fisher, Cambridge, Massachusetts,
USA). The experimental procedures for preparation of
CA-4 and the target compounds 6-14, as well as copies of
1H-NMR and 13C-NMR, can be found in Additional file 2.Biological activity evaluation
Cell culture and antitumor activity
Four human tumor cell lines were tested in the current
study, including MDA-MB-231 breast cancer, MCF-7
breast cancer, K562 leukemia, A549 lung cancer cells,
which were obtained from the Immune Pharmacological
Research Institute at Shandong University. All of the test
compounds were dissolved in DMSO at 10 μM, and sub-
sequently diluted to the appropriate concentration prior
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lines were cultured in an RPMI 1640 medium (GIBCO)
supplemented with 10% bovine fetal calf serum. The cell
lines were maintained at 37°C in a humidified atmos-
phere containing 5% CO2 in an incubator. The cancer
cells were seeded in 96-well plates and treated with dif-
ferent concentrations of the synthesized compounds
after 6 h of incubation. Five replicate wells were used for
each concentration, and the concentration of DMSO
used in each case never exceeded 0.1%, so that it would
not affect the growth of the cells. The treated cells were
incubated for 72 h and 10 μL of the cell proliferation re-
agent WST-1 was then added to each well. The wells
were then incubated at 37°C under 5% CO2 in a humi-
dified incubator for 2 h. The absorbance was measured
in a microplate reader at 450/630 nm. The IC50 values
were then calculated according to the percentage of
growth in the presence of the test compounds.
Cell cycle analysis
For the cell cycle analysis experiments, MCF-7 cells
(3 × 105) were seeded in 6-well plates and treated with
different concentrations of CA-4 and CA-4E (i.e., 0, 1.5,
and 3 nM). The cells were then incubated for 24 and 32 h
before being washed twice with ice-cold PBS, harvested,
fixed with ice-cold PBS in 75% ethanol and stored at 4°C
overnight. The cells were then incubated with RNase A
(0.1 mg/mL) at 37°C for 45 min, and then stained with
propidium iodide (0.1 mg/mL) for 30 min on ice in the
absence of light. The DNA contents of 10,000 events were
measured by flow cytometery and the cell cycle profiles
were analyzed on the basis of the DNA content histo-
grams [21].
Cell apoptosis with FITC-Annexin V/PI double staining
Trypsin without EDTA was used to digest and collect the
control group and the cells treated with 1.5 and 3 nM of
CA-4 and CA-4E. Flow cytometry was performed accor-
ding to the manufacturer’s procedure provided with the
apoptosis detection kit. The MCF-7 cells were washed
twice with PBS and centrifuged at 650 × g for 5 min. A
binding buffer suspension (500 μL) was added to the cells
followed by 5 μL of the FITC-Annexin V mix, and the
resulting mixture was held at 4°C for 20 min. Two and a
half microliters of the PI mix was then added to the mix-
ture, and the resulting cell suspension was held at 4°C in
the absence of light for 15 min. Flow cytometry was
performed using a BD FACS Caliber instrument (BD -
Biosciences, San Jose, USA).
Conclusion
In summary, we have successfully synthesized a novel
series of CA-4 analogues bearing a 3’-O-substituted car-
bonic ether moiety and evaluated their antitumor activitiesagainst four tumor cell lines using a WST-1-based cytoto-
xicity assay. The results revealed that all of the synthesized
compounds exhibited high levels of antitumor activity,
with most of the compounds exhibiting similar levels of
bioactivity to CA-4. Compound CA-4E, in particular,
showed much higher levels of bioactivity than CA-4, with
IC50 values in the range of 1 to 180 nM. For this reason,
CA-4E was selected as the best representative of the syn-
thesized compounds to investigate the antitumor mecha-
nism of these analogues by assessing the effect of CA-4E
on the cell cycle and apoptosis. The cell cycle results dem-
onstrated that CA-4E induced time- and dose-dependent
G2/M arrest in the same way as CA-4, although the effect
of CA-4E was more pronounced than that of CA-4. Fur-
thermore, the apoptosis data showed that CA-4E induced
cellular apoptosis in a dose-dependent manner. Taken to-
gether, these results suggest that the anticancer activity of
CA-4E is worthy of further study, with CA-4E represen-
ting a potential new anticancer drug candidate.
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